Author

Chenyu Zhang

University of California, BerkeleyORCID 0000-0002-3199-9422Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioinformatics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

Alissa BockmaniD· 2 shared David H. RauletiD· 2 shared Elizabeth AndrewsiD· 2 shared Michel J.P. DuPageiD· 2 shared Yeara JoiD· 2 shared Abigail MendeiD· 1 shared Alejandro N Medina· 1 shared Alexandros KarampatzakisiD· 1 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Alissa BockmanORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ITPKB is a conserved regulator of natural killer cell desensitization/education that constrains antitumor immunity

Yeara Jo, Alexandros Karampatzakis, Seung Won Lee, Alice Peng, Zaina Ghouri, Monsserratt Moya, Elizabeth Andrews, Harrison Sudholz, Chenyu Zhang, Berna Bou Tayeh, Alejandro N Medina, Jiucheng Ding, Robert A. Saxton, Ziyang Zhang, Yang Shi, , David H. Raulet

This study identifies ITPKB as a regulator of NK cell desensitization, showing its inhibition enhances antitumor immunity in murine and human models.

bioRxiv · Jul 17, 2026 · PreprintImmunology

A residual-ratio framework for auditing transcriptomic gene signatures against background expression structure

Ying Zhu, Chenyu Zhang, Vince D. Calhoun, Yuda Bi

This paper introduces a residual-ratio framework to audit transcriptomic gene signatures by quantifying their independence from background expression structure, showing it discriminates biological signatures from random gene sets across multiple cancer types.

bioRxiv · Apr 14, 2026 · PreprintBioinformatics

Intra-Tumoral Treg Ablation Unleashes NK Cell-Mediated Control of CD8 T Cell-Resistant Tumors

Chenyu Zhang, Charles Chien, Eglė Jurgaitytė, Koharu Sakiyama, Alissa Bockman, Yeara Jo, Seungwon Lee, Stephanie L. Silveria, Elizabeth Andrews, Abigail Mende, Lily Zhang, K. Christopher García, Allon Wagner, Michel J.P. DuPage, David H. Raulet

Intra-tumoral Treg ablation enhances NK cell-mediated tumor control by restoring IL-2 production, effective against both MHC I+ and MHC I- cancers without systemic toxicity.

Science Immunology · Apr 10, 2026Peer-reviewedImmunology

Intratumoral Treg ablation is sufficient to mediate tumor control systemically without autoimmunity

Alissa Bockman, Brenna J. Gittins, Chenyu Zhang, Jessica Shuk-Chun Hung, Mariela Moreno Ayala, Dorothée Saddier Axe, Brian M. Weist, Michel J.P. DuPage

The paper shows that ablating tumor-infiltrating Tregs systemically controls tumors without autoimmunity, primarily through CD4+ T cells and cDC2s.

bioRxiv · Jun 26, 2025 · PreprintCancer Biology